These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 36517487)

  • 1. Management of patients with lower-risk myelodysplastic syndromes.
    Brunner AM; Leitch HA; van de Loosdrecht AA; Bonadies N
    Blood Cancer J; 2022 Dec; 12(12):166. PubMed ID: 36517487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raising the bar for lower-risk myelodysplastic syndromes.
    Venugopal S; Sekeres MA
    Leuk Lymphoma; 2023 Jun; 64(6):1082-1091. PubMed ID: 37029589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M; Zeidan AM
    Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What constitutes meaningful improvement in myelodysplastic syndromes?
    Chandhok NS; Sekeres MA
    Leuk Lymphoma; 2022 Nov; 63(11):2528-2535. PubMed ID: 35699987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current treatment strategies for myelodysplastic syndromes].
    Suzuki T
    Rinsho Ketsueki; 2015 Oct; 56(10):1985-95. PubMed ID: 26458437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.
    Rodriguez-Sevilla JJ; Adema V; Garcia-Manero G; Colla S
    Cell Rep Med; 2023 Feb; 4(2):100940. PubMed ID: 36787738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes.
    Hochman MJ; DeZern AE
    Clin Lymphoma Myeloma Leuk; 2024 Sep; 24(9):573-582. PubMed ID: 38594129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G
    Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
    Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myelodysplastic syndromes: clinical practice guidelines in oncology.
    Greenberg PL; Attar E; Bennett JM; Bloomfield CD; Borate U; De Castro CM; Deeg HJ; Frankfurt O; Gaensler K; Garcia-Manero G; Gore SD; Head D; Komrokji R; Maness LJ; Millenson M; O'Donnell MR; Shami PJ; Stein BL; Stone RM; Thompson JE; Westervelt P; Wheeler B; Shead DA; Naganuma M
    J Natl Compr Canc Netw; 2013 Jul; 11(7):838-74. PubMed ID: 23847220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Jain AG; Ball S; Aguirre L; Al Ali N; Kaldas D; Tinsley-Vance S; Kuykendall A; Chan O; Sweet K; Lancet JE; Padron E; Sallman DA; Komrokji R
    Haematologica; 2024 Jul; 109(7):2157-2164. PubMed ID: 38299605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel combinations to improve hematopoiesis in myelodysplastic syndrome.
    Syed K; Naguib S; Liu ZJ; Cimmino L; Yang FC
    Stem Cell Res Ther; 2020 Mar; 11(1):132. PubMed ID: 32197634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
    Sekeres MA; Taylor J
    JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
    Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M
    J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.